The Cardiovascular National Innovation Center (CNIC) recently hosted its 9th Annual Cardiovascular Bioengineering Symposium, an immersive, three-day event that united world-leading scientists, engineers, and clinicians on the front lines of heart failure treatment and cardiovascular regeneration.

This year’s symposium spotlighted transformative discoveries across cardiac stem cell biology, vascular biology, metabolism, and targeted therapeutics. With a strong focus on translational research, discussions centered on next-generation strategies to rebuild damaged heart tissue, slow disease progression, and personalize care for patients with advanced heart failure.

A key theme that emerged was the pivotal role of immune cell dysregulation in driving diseases like atherosclerosis and inflammatory cardiomyopathies. Researchers showcased how cutting-edge tools, like tissue-engineered models and organ-on-a-chip systems, are redefining how we study immune responses and design tailored therapies.

Beyond presentations, the event offered collaborative forums and interdisciplinary panels that encouraged knowledge-sharing and innovation across traditional boundaries. By bringing together biologists, engineers, and clinicians, CNIC reinforced the need for unified approaches to the complex challenges of cardiovascular disease.

This year’s organizing committee included Jianyi “Jay” Zhang, MD, Ph.D., FAHA, professor and chair in the Department of Biomedical Engineering and Than Nguyen, Ph.D., Assistant Professor in the Department of Biomedical Engineering and Informatics Institute.

As cardiovascular bioengineering continues to evolve at breakneck speed, the symposium highlighted CNIC’s ongoing commitment to leading global discourse and accelerating breakthroughs in cardiovascular therapeutics.

Learn more about this event at cnic-conference.com.